Former Biden global health security lead Stephanie Psaki asks: Why would the Trump administration reject a deal that ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

But it’s unclear if the evidence provided to support continued use of fluoridated supplements will matter. The FDA said in ...

As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are ...

This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

Columbia University agreed Wednesday to pay more than $220 million in a deal with the Trump administration to restore federal ...

UnitedHealth Group on Thursday confirmed the Department of Justice has launched both criminal and civil investigations into ...

And other biotech news brought to you by The Readout.

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Cognitive behavioral therapy is known to be beneficial for people with chronic pain, but accessing that care can be difficult ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech companies to pursue them, writes Alnylam CEO.